In the cooperative research and development agreement, the partners will use Apertura's TfR1 CapX capsid to deliver a gene therapy to the central nervous system.
The Phase I/II trial will enroll pediatric patients with the seizure-causing condition who will be dosed every six months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results